SARS-CoV-2 3CLpro-IN-36 

SARS-CoV-2 3CLpro-IN-36 is a SARS-CoV-2 3CLpro inhibitor and antiviral agent with a human sub-micromolar IC₅₀ against SARS-CoV-2 3CLpro.SARS-CoV-2 3CLpro-IN-36 forms a covalent bond with catalytic Cys145 of SARS-CoV-2 3CLpro; its tetrazole core occupies the S1 pocket and interacts with His163, while its chloroacetamide carbonyl forms hydrogen bonds with the backbone amides of Gly143 and Ser144 in the oxyanion hole.SARS-CoV-2 3CLpro-IN-36 reduces SARS-CoV-2 replication in infected cells.SARS-CoV-2 3CLpro-IN-36 can be used for the research of SARS-CoV-2 infection^[1].

SARS-CoV-2 3CLpro-IN-36 covalently binds to the catalytic site Cys145 and interacts with key active site residues including His163, Gly143 and Ser144, inhibiting the enzymatic activity of purified recombinant SARS-CoV-2 3CLpro with an IC₅₀ of 827 nM^[1].
SARS-CoV-2 3CLpro-IN-36 (0.125-2 μM; added 1 h post initial infection, treated for 23 h) exhibits dose-dependent antiviral activity against SARS-CoV-2 in A549-hACE2 cells, reducing viral mRNA expression, viral protein expression, and progeny viral titer at concentrations ranging from 0.125 to 2 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

494.97

C₂₈H₂₃ClN₆O

ClCC(N(C1=CC=C(C2=CC=CC=C2)C=C1)C(C3=NN=NN3CC4=CC=CC=C4)C5=CC=CN=C5)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. van der Straat R, et al. Ugi-Tetrazole-Derived α-Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV-2 3CLpro[J]. ACS Medicinal Chemistry Letters, 2026.